US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

51.03

0.0000

Volume:- -

Turnover:- -

Market Cap:25.52M

PE:- -

High:51.03

Open:51.03

Low:51.03

Close:51.03

52wk High:52.94

52wk Low:50.07

Shares:500.00K

Float Shares:500.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor

ABBISKO-B (02256): ABBISK Medicine's CSF-1R Inhibitor Beijiemai® Approved by China's NMPA

Plus Therapeutics Expands CNSide Assay Platform to State of California

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Press Release: Plus Therapeutics Updates on CNSide(R) Diagnostic Platform Launch

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CSF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":51.03,"timestamp":1774296000000,"preClose":51.03,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Closed","change":0,"latestTime":"03-23 16:00:00 EDT","open":51.03,"high":51.03,"low":51.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774339200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":51.03,"sharesOutstanding":500000,"nav":51.331892,"aum":25665950,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0,"high":51.03,"amplitude":0,"preClose":51.03,"low":51.03,"week52Low":50.07,"pbRate":"--","week52High":52.9425,"institutionHeld":0,"latestPrice":51.03,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":51.03,"prevYearClose":51.03,"prevWeekClose":51.03,"prevMonthClose":51.03,"prevQuarterClose":51.03,"fiveDayClose":51.03,"twentyDayClose":51.03,"sixtyDayClose":51.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-24","symbol":"CSF","reason":null,"defaultRemindTime":1745501400000,"announcedDate":"2025-04-23","type":"delisting","dateTimestamp":1745467200000},{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-17","recordDate":"2017-01-19","paymentDate":"2017-01-20","value":0.0124628,"currency":"USD"},{"executeDate":"2017-02-14","recordDate":"2017-02-16","paymentDate":"2017-02-17","value":0.0180041,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-21","value":0.072161,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-19","value":0.02261,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-16","value":0.048374,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621261758","title":"Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621261758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621261758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:05","pubTimestamp":1774022700,"startTime":"0","endTime":"0","summary":"Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March  20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/20/3259865/0/en/Results-from-Real-World-Long-Term-Treatment-Persistence-with-LEQEMBI-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","AD","UBCP","CSF","BK4023","BK4080","MCI","CDR","LU1169590202.USD","BK4132","PD","LU1169589451.USD"],"gpt_icon":0},{"id":"2620228692","title":"Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620228692","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620228692?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919800,"startTime":"0","endTime":"0","summary":"Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercializationHOUST","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3258891/0/en/Plus-Therapeutics-to-Present-New-Analysis-at-ISPOR-Showing-CNSide-May-Reduce-Leptomeningeal-Metastases-Healthcare-Costs-by-40.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XLV","BK4139","LU0029874061.USD","CNS","NCI","XBI","BK4585","BK4581","CSF","BK4539","BK4588","LABU","BK4135","LU0128526141.USD","BK4202","HCSG","BK4137","LENZ"],"gpt_icon":0},{"id":"2620825580","title":"Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825580","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825580?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:15","pubTimestamp":1773836100,"startTime":"0","endTime":"0","summary":"Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258138/0/en/Gain-Therapeutics-Presents-Additional-Clinical-and-Biomarker-Data-from-Phase-1b-Clinical-Study-of-GT-02287-and-Preclinical-Data-from-Novel-Chemical-Series-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GANX","DDC","LU1169590202.USD","BK4585","AD","BK4212","BK4588","BK4119","GT","BK4023","CSF","LU1169589451.USD","PD","BK4139","BK4132"],"gpt_icon":0},{"id":"2620255389","title":"Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255389","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255389?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:00","pubTimestamp":1773831600,"startTime":"0","endTime":"0","summary":"– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels following 28","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258013/0/en/Arvinas-Announces-Positive-Phase-1-Data-for-ARV-102-Showing-Greater-Than-50-LRRK2-Degradation-in-the-CSF-of-Patients-with-Parkinson-s-Disease-Treated-for-28-Days.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","PD","LU1169589451.USD","LU1169590202.USD","CSF","MD","BK4196","PSP"],"gpt_icon":0},{"id":"2618601754","title":"Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601754","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618601754?lang=en_us&edition=fundamental","pubTime":"2026-03-10 09:33","pubTimestamp":1773106380,"startTime":"0","endTime":"0","summary":"HONG KONG, March 10, 2026 /PRNewswire/ -- Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics , a global leader in in advanced brain health diagnostics.The partnership will introduce the PrecivityAD2 blood test to healthcare professionals across Hong Kong, enabling access to C2N's innovative technology that aids in the diagnosis of Alzheimer's disease.The PrecivityAD2 test is intended for individuals aged 50 years and older with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer's disease or other causes of cognitive decline. The PrecivityAD2 test detects the presence or absence of brain amyloid pathology, a key hallmark of Alzheimer's disease, and supports a clinician's diagnosis.\"Our collaboration with C2N reinforces Codex Genetics' commitment to advancing precision medicine and to improving access to cutting-edge diagnostic technologies in Hong Kong and the regio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/codex-genetics-partners-with-c2n-diagnostics-to-introduce-the-precivityad2-blood-test-in-hong-kong-facilitating-access-to-innovative-alzheimers-disease-diagnostics-302708754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7141","CSF","CSF.AU"],"gpt_icon":0},{"id":"2614084111","title":"Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2614084111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614084111?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:00","pubTimestamp":1772020800,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  25, 2026  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244474/0/en/Tiziana-Life-Sciences-Announces-New-Biomarker-Data-Showing-Nasal-Foralumab-Downregulates-CSF-Inflammation-Upregulates-Neuroprotective-Pathways-and-Correlates-with-Reduced-Microglia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0950375773.USD","LU0823417653.USD","LU1585245621.USD","LU1244550221.USD","LU0158827948.USD","LU0795875169.SGD","LU2506952097.USD","LU0912757837.SGD","LU0640476718.USD","LU2506952170.USD","LU1791710582.SGD","LU2357305700.SGD","LU1989772923.USD","LU1668664300.SGD","LU2089284900.SGD","LU2506951875.HKD","LU1043141123.HKD","LU1430594728.SGD","LU0882574139.USD","LU2506951958.HKD","LU1720051108.HKD","LU0158827781.USD","LU2028103732.USD","LU1043141396.HKD","BK4532","LU0795875086.SGD","LU1162221912.USD","LU2133065610.SGD","LU1791710400.SGD","BK4085","LU0006306889.USD","LU0225283273.USD","LU1280957306.USD","LU2023251221.USD","LU0426417589.USD","CSF","LU2271345857.HKD","LU1732799900.SGD","LU2347655156.SGD","BK4504","LU0314104364.USD","LU0971096721.USD","LU0006061336.USD","BK4533","EA","LU2111349929.HKD","LU0557290698.USD","LU1074936037.SGD","LU1244550494.USD","BK4588"],"gpt_icon":0},{"id":"2609868445","title":"Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™","url":"https://stock-news.laohu8.com/highlight/detail?id=2609868445","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609868445?lang=en_us&edition=fundamental","pubTime":"2026-02-06 03:00","pubTimestamp":1770318000,"startTime":"0","endTime":"0","summary":"Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness esta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3233366/0/en/Denali-Therapeutics-Presents-Enzyme-TransportVehicle-Progress-Across-Three-Clinical-Programs-for-Treatment-of-Lysosomal-Storage-Disorders-at-2026-WORLDSymposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TV","CNS","BK4539","BK4007","LU2065732104.USD","PRGS","ETV","BK4097","LENZ","BK4100","CSF","BK4135","BBB","BK4139","GAA"],"gpt_icon":0},{"id":"2608871508","title":"Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871508","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871508?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123600,"startTime":"0","endTime":"0","summary":"Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3230975/20739/en/Ultragenyx-Announces-Positive-Longer-Term-Data-Demonstrating-Treatment-with-UX111-Gene-Therapy-Results-in-Sustained-Significant-Reductions-in-CSF-HS-and-Continued-Meaningful-Improv.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF"],"gpt_icon":0},{"id":"2601315892","title":"Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287","url":"https://stock-news.laohu8.com/highlight/detail?id=2601315892","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601315892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:00","pubTimestamp":1767700800,"startTime":"0","endTime":"0","summary":"Results to be discussed in KOL event today at 10 a.m. ETBETHESDA, Md., Jan.  06, 2026  (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechno","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213471/0/en/Gain-Therapeutics-Highlights-Biomarker-Evidence-Supporting-Disease-Modifying-Potential-of-GT-02287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GT","BK4119","BK4023","BK4585","GANX","LU1169590202.USD","CSF","PD","LU1169589451.USD","BK4139"],"gpt_icon":0},{"id":"2595975697","title":"The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)","url":"https://stock-news.laohu8.com/highlight/detail?id=2595975697","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595975697?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:00","pubTimestamp":1767099600,"startTime":"0","endTime":"0","summary":"Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and nor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/30/3211341/0/en/The-New-England-Journal-of-Medicine-Publishes-Phase-1-2-Study-of-Denali-Therapeutics-Tividenofusp-Alfa-DNL310-for-Hunter-Syndrome-MPS-II.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4100","BK4539","TV","BK4135","CNS","BBB","CSF","BK4139","LENZ"],"gpt_icon":0},{"id":"2593048418","title":"Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor","url":"https://stock-news.laohu8.com/highlight/detail?id=2593048418","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593048418?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:29","pubTimestamp":1766402940,"startTime":"0","endTime":"0","summary":"Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically dev","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/22/3209070/0/en/Abbisko-Therapeutics-CSF-1R-Inhibitor-Pimicotinib-Approved-by-the-China-NMPA-Addressing-the-Treatment-Gap-for-Tenosynovial-Giant-Cell-Tumor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4139","ORR","BK4161","CSF","BK4007","BK4539","CR","LENZ","BK4081"],"gpt_icon":0},{"id":"1181395345","title":"ABBISKO-B (02256): ABBISK Medicine's CSF-1R Inhibitor Beijiemai® Approved by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1181395345","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181395345?lang=en_us&edition=fundamental","pubTime":"2025-12-22 16:41","pubTimestamp":1766392862,"startTime":"0","endTime":"0","summary":"On December 22, 2025, ABBISKO-B (02256) announced that its subsidiary, Shanghai ABBISK Biopharmaceutical Co., Ltd. (\"ABBISK Medicine\"), received approval from China's National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","LU2488822045.USD","LU2778985437.USD","CSF","159938","02256","LU2476274720.SGD","IE00B5MMRT66.SGD","BK1515","IE00BPRC5H50.USD","LU2476274308.USD","BK1161","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2590515350","title":"Plus Therapeutics Expands CNSide Assay Platform to State of California","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515350","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515350?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456200,"startTime":"0","endTime":"0","summary":"CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec.  11, 2025  (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203802/0/en/Plus-Therapeutics-Expands-CNSide-Assay-Platform-to-State-of-California.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","BK4139","IE00BGHQF748.EUR","LU0061475181.USD","LU1894683264.USD","STT","BK4588","CSF","LU1883839398.USD","BK4007","CNS","BK4539","LU1894683348.USD","BK4135","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4585","LENZ"],"gpt_icon":0},{"id":"2590134045","title":"AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2590134045","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590134045?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454400,"startTime":"0","endTime":"0","summary":"AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for the first time, that targeting underlying a-syn pathology with","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203753/0/en/AC-Immune-Positive-Interim-Phase-2-Data-on-ACI-7104-056-Support-Potential-Slowing-of-Progression-of-Parkinson-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","ACIU","BK4023","BK4135","ACI","CSF","CNS","BK4113","LU1169590202.USD","BK4139","LU1169589451.USD"],"gpt_icon":0},{"id":"2588872548","title":"BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2588872548","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588872548?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:00","pubTimestamp":1764856800,"startTime":"0","endTime":"0","summary":"BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cy","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/04/3199871/0/en/BioAge-Announces-Positive-Interim-Phase-1-Data-for-BGE-102-a-Novel-Brain-Penetrant-NLRP3-Inhibitor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF"],"gpt_icon":0},{"id":"2588186061","title":"New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2588186061","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588186061?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:40","pubTimestamp":1764711600,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Dec.  02, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3198449/0/en/New-Data-Presented-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-lecanemab-irmb-on-Neurotoxic-A%CE%B2-Protofibrils-in-CSF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAA","BK4132","CSF","MCI","ARIA","AD"],"gpt_icon":0},{"id":"2584394961","title":"Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584394961","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584394961?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:30","pubTimestamp":1763641800,"startTime":"0","endTime":"0","summary":"HOUSTON, Nov.  20, 2025  (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary ofPlus Therapeutics, Inc.(Nasdaq:PSTV) (“Plus” or the “Company”), announced today that it has signed a n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191797/0/en/Plus-Therapeutics-Secures-National-Coverage-Agreement-with-Humana-for-CNSide-Cerebrospinal-Fluid-Assay-for-Metastatic-CNS-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","SG9999014021.USD","LU0208291251.USD","LU0211331839.USD","SG9999014005.SGD","BK4588","LU0238689110.USD","SG9999014013.SGD","BK4566","BK4007","LU0170899867.USD","CSF","BK4533","LU0417517546.SGD","LU1093756325.SGD","LU0390134368.USD","NHLD","LU0348723411.USD","LU1983260115.SGD","BK4539","LU0320765489.SGD","BK4154","BK4135","LENZ","LU0266013472.USD","BK4585","LU0070302665.USD","LU0256863811.USD","LU1093756168.USD","BK4139","HUM"],"gpt_icon":0},{"id":"2577282400","title":"Press Release: Plus Therapeutics Updates on CNSide(R) Diagnostic Platform Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2577282400","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577282400?lang=en_us&edition=fundamental","pubTime":"2025-10-21 19:30","pubTimestamp":1761046200,"startTime":"0","endTime":"0","summary":"Appoints new leadership in commercial strategy and technical operations. HOUSTON, Oct. 21, 2025  -- Plus Therapeutics, Inc.  , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system  cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC's, Cerebrospinal Fluid  Tumor Cell Enumeration laboratory developed test .Recent accomplishments include expansion of the CNSide manufacturing footprint, advancements in commercial readiness and appointments in key leadership positions to propel the CNSide diagnostic business forward. To lead commercialization strategy, Russ Havranek, MS, MBA, has been promoted to Executive Vice President, Commercial and Corporate Strategy. In addition, Daniel Ortega, MBA, has been promoted to the position of Vice President, Development and Technical Operations to lead our diagnostic capabilities a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","LENZ","BK4232","STRK","BK4007","BK4585","BK4596","BK4516","BK4135","CSF","BK4539","CNS","R","PSTV","BK4595","BK4600","BK4139","BK4023","BK4588"],"gpt_icon":1},{"id":"2574197687","title":"Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2574197687","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574197687?lang=en_us&edition=fundamental","pubTime":"2025-10-10 05:23","pubTimestamp":1760044980,"startTime":"0","endTime":"0","summary":"New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development.   FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 —a pivotal biomarker in Alzheimer's disease research and other tauopathies. This first-of-its-kind assay is the only brain-derived single-plex solution available, setting a new benchmark for precision and CNS specificity in neurodegenerative disease research.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2792912/Alamar_Biosciences_Inc_NULISA_BD.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2792912/Alamar_Biosciences_Inc_NULISA_BD.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/alamar-biosciences-launches-nulisaqpcr-bd-ptau217-assay-a-breakthrough-in-non-invasive-brain-specific-biomarker-detection-for-alzheimers-disease-research-302580276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF.AU","CSF","BK7141"],"gpt_icon":0},{"id":"2574151683","title":"Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2574151683","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574151683?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:25","pubTimestamp":1760009100,"startTime":"0","endTime":"0","summary":"– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/09/3164032/0/en/Alterity-Therapeutics-Presents-Positive-Data-from-ATH434-Phase-2-Trial-at-the-2025-International-Congress-of-Parkinson-s-Disease-and-Movement-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","BK4143","BK4539","LU1923622291.USD","LU2125909759.SGD","BK4139","LU2125909916.SGD","LU2211815571.USD","LU0728928796.USD","MSA","BK4007","LENZ","LU1815336091.USD","LU0053671581.USD","ATHE","LU0757428866.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}]}}